Literature DB >> 15928920

Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.

Yongjun Jiang1, Jianwei Zou, Chunshan Gui.   

Abstract

Cyclin-dependent kinases (Cdks) play important roles in the regulation of the cell cycle. Their inhibitors have entered clinical trials to treat cancer. Very recently, Davis et al. (Nat Struct Biol 9:745-749, 2002) have found a ligand NU6102, which has a high affinity with cyclin-dependent kinase 2 (K(i) = 6 nM) but a low affinity with cyclin-dependent kinase 4 (K(i) = 1,600 nM). To understand the selectivity, we use homology modeling, molecular docking, molecular dynamics and free-energy calculations to analyze the interactions. A rational 3D model of the Cdk4-NU6102 complex is built. Asp86 is a key residue that recognizes NU6102 more effectively with Cdk2 rather than Cdk4. Good binding free energies are obtained. Energetic analysis reveals that van der Waals interaction and nonpolar contributions to solvent are favorable in the formation of complexes and the sulfonamide group of the ligand plays a crucial role for binding selectivity between Cdk2 and Cdk4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928920     DOI: 10.1007/s00894-005-0263-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  21 in total

1.  Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7.

Authors:  L T Chong; Y Duan; L Wang; I Massova; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 2.  Therapeutic potential of targeting the cell cycle.

Authors:  K R Webster
Journal:  Chem Res Toxicol       Date:  2000-10       Impact factor: 3.739

Review 3.  Cyclin-dependent kinase inhibitors for treating cancer.

Authors:  P L Toogood
Journal:  Med Res Rev       Date:  2001-11       Impact factor: 12.944

Review 4.  Small molecules as inhibitors of cyclin-dependent kinases.

Authors:  Axel Huwe; Ralph Mazitschek; Athanassios Giannis
Journal:  Angew Chem Int Ed Engl       Date:  2003-05-16       Impact factor: 15.336

5.  Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.

Authors:  T Honma; K Hayashi; T Aoyama; N Hashimoto; T Machida; K Fukasawa; T Iwama; C Ikeura; M Ikuta; I Suzuki-Takahashi; Y Iwasawa; T Hayama; S Nishimura; H Morishima
Journal:  J Med Chem       Date:  2001-12-20       Impact factor: 7.446

6.  A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.

Authors:  T Honma; T Yoshizumi; N Hashimoto; K Hayashi; N Kawanishi; K Fukasawa; T Takaki; C Ikeura; M Ikuta; I Suzuki-Takahashi; T Hayama; S Nishimura; H Morishima
Journal:  J Med Chem       Date:  2001-12-20       Impact factor: 7.446

7.  Evaluation of the conformational free energies of loops in proteins.

Authors:  K C Smith; B Honig
Journal:  Proteins       Date:  1994-02

Review 8.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

Review 9.  CDK inhibition and cancer therapy.

Authors:  M D Garrett; A Fattaey
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

10.  A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.

Authors:  Peter A Sims; Chung F Wong; J Andrew McCammon
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

View more
  3 in total

1.  Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

2.  PatchSurfers: Two methods for local molecular property-based binding ligand prediction.

Authors:  Woong-Hee Shin; Mark Gregory Bures; Daisuke Kihara
Journal:  Methods       Date:  2015-09-30       Impact factor: 3.608

3.  Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.

Authors:  Muhammad Imtiaz Shafiq; Thomas Steinbrecher; Ralf Schmid
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.